DocMorris Shares Surge Despite 2025 Loss Forecast
DocMorris shares are on a short-term upward trajectory, currently among the day's winners on the exchange. However, the company faces a challenging fundamental environment, with analysts forecasting a loss per share in 2025.
The stock's recent gains are driven by a technical buy signal, with no new fundamental news since August 19. Despite this, 53% of analysts recommend buying DocMorris shares, while 40% advise holding. Only 7% recommend selling. Financially, DocMorris reported a revenue increase of 34% to 1.343 billion CHF, but it also posted an EBITDA loss of 65 million CHF and a net loss of 146 million CHF, indicating ongoing struggles.
The company's valuation is seen as a tightrope walk, with its future dependent on providing fresh impetus, particularly regarding e-prescriptions in Germany.
DocMorris shares continue to gain, up 1.2 percent on the SIX SX. While analysts are cautiously optimistic, the company's financial losses and challenging fundamental environment warrant caution among investors.
